Search Result

Results for "

HDACs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (416) Adenosine Receptor (8) Akt (1) Aminopeptidase (1) AMPK (1) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (129) Autophagy (40) Bcl-2 Family (2) Bcr-Abl (1) Beta-lactamase (5) c-Met/HGFR (2) Calcium Channel (1) Caspase (4) CCR (1) CDK (6) Cholinesterase (ChE) (5) COX (1) Cytochrome P450 (2) DNA/RNA Synthesis (4) Drug-Linker Conjugates for ADC (2) EBV (1) EGFR (1) Endogenous Metabolite (14) Epigenetic Reader Domain (3) Epoxide Hydrolase (1) Estrogen Receptor/ERR (1) Ferroptosis (1) FGFR (1) Filovirus (2) FLT3 (2) Fluorescent Dye (2) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) G-quadruplex (1) Guanylate Cyclase (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (4) Histone Demethylase (5) Histone Methyltransferase (3) HIV (17) HPV (2) HSP (5) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Interleukin Related (5) Isotope-Labeled Compounds (8) JAK (5) Keap1-Nrf2 (1) MDM-2/p53 (3) Microtubule/Tubulin (8) Mitochondrial Metabolism (1) Mitophagy (14) MMP (1) Monoamine Oxidase (3) mTOR (5) MyD88 (1) NAMPT (2) Necroptosis (1) NF-κB (4) Notch (10) Organoid (3) Oxidative Phosphorylation (1) PAK (1) Parasite (8) PARP (3) Phosphatase (1) Phosphodiesterase (PDE) (6) PI3K (8) Pim (1) PKD (1) Potassium Channel (1) PROTACs (14) Proteasome (1) Reactive Oxygen Species (5) REV-ERB (1) SHP2 (1) Sirtuin (1) Small Interfering RNA (siRNA) (33) Sodium Channel (1) Tau Protein (1) TNF Receptor (4) Toll-like Receptor (TLR) (1) Topoisomerase (5) Tyrosinase (1) VD/VDR (1) VEGFR (2) Virus Protease (5)
By Research Areas:	Cancer (364) Cardiovascular Disease (7) Endocrinology (2) Infection (24) Inflammation/Immunology (26) Metabolic Disease (9) Neurological Disease (47)
Click Chemistry:	Alkynes (7)

478

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114414

HDACs/mTOR Inhibitor 1 1 Publications Verification	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .

HY-144332

*PHD2/HDACs-IN-1*	HDAC HIF/HIF Prolyl-Hydroxylase	Cancer
PHD2/HDACs-IN-1 is a potent *PHD2/HDACs* hybrid inhibitor (IC₅₀s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .

HY-162349

*PARP7/HDACs-IN-1*	HDAC PARP	Cancer
PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting *PARP7/HDAC* with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC₅₀s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6) . br/ .

HY-150859

HDAC ligand-1

HDAC Cancer

HDAC ligand-1 is a HDAC ligand that can be used to synthesize PROTAC HDAC degraders .

HDAC ligand-1	HDAC	Cancer
HDAC ligand-1 is a *HDAC* ligand that can be used to synthesize PROTAC HDAC degraders .

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-144102

HDAC-IN-29

HDAC Cancer

HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HDAC-IN-29	HDAC	Cancer
HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HY-157152

HDAC-IN-65	HDAC	Cancer
HDAC-IN-65 ( compound 6) is a selective histone deacetylase (HDAC) inhibitor with IC₅₀ value of 2.5μM. HDAC-IN-65 is a prodrug with very good bioreductive properties .

HY-149529

HDAC8-IN-5

HDAC Cancer

HDAC8-IN-5 (Compound 6a) is a HDAC8 inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .

HDAC8-IN-5	HDAC	Cancer
HDAC8-IN-5 (Compound 6a) is a *HDAC8* inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .

HY-147934

HDAC8-IN-3	HDAC Apoptosis	Cancer
HDAC8-IN-3 (compound P19) is a potent *HDAC8* inhibitor with IC₅₀ value of 9.3 μM and produces thermal stabilization. HDAC8-IN-3 has cytotoxicity and induces apoptosis in leukemic cell lines .

HY-163430

HDAC-IN-71	HDAC Apoptosis	Cancer
HDAC-IN-71 (Compound 17q) is a potent *HDAC* inhibitor with IC₅₀ values of 12.6, 14.1, 20, 3, and 72 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. HDAC-IN-71 induces apoptosis and can be used in cancer research .

HY-149284

JAK/HDAC-IN-3

JAK HDAC Cancer

JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .

*JAK/HDAC-IN-3*	JAK HDAC	Cancer
JAK/HDAC-IN-3 (13a) is a dual JAK and *HDAC* inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .

HY-151897

HDAC-IN-49	HDAC	Cancer
HDAC-IN-49 is a potent unselective *HDAC* (HDAC) inhibitor with IC₅₀s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .

HY-15433A

Quisinostat dihydrochloride 5+ Cited Publications JNJ-26481585 dihydrochloride	HDAC Apoptosis Autophagy	Cancer
Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally available, potent pan-HDAC inhibitor with IC₅₀s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity .

HY-15433

Quisinostat 5+ Cited Publications JNJ-26481585	HDAC Apoptosis Autophagy	Cancer
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC₅₀ values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity . Quisinostat can induce autophagy in neuroblastoma cells .

HY-149239

*Topo II/HDAC-IN-2*	Topoisomerase HDAC Apoptosis	Cancer
Topo II/HDAC-IN-2 (8d) exhibits excellent dual inhibitory activities against Topo II and *HDAC. Topo II/HDAC*-IN-2 (8d) induces apoptosis .

HY-149238

*Topo II/HDAC-IN-1*	Topoisomerase HDAC Apoptosis	Cancer
Topo II/HDAC-IN-1 (7d) exhibits excellent dual inhibitory activities against Topo II and *HDAC. Topo II/HDAC*-IN-1 (8d) induces apoptosis .

HY-145815

JPS014	HDAC PROTACs	Cancer
JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC). JPS014 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145816

JPS016	HDAC PROTACs	Cancer
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145818

JPS035	HDAC PROTACs	Cancer
JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145819

JPS036	HDAC PROTACs	Cancer
JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145816A

JPS016 TFA	HDAC PROTACs	Cancer
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-150577

HDAC-IN-45	HDAC	Cancer
HDAC-IN-45 (Compound 14) is a small molecule *HDAC* inhibitor and has anticancer activity, also can forms a hydrogen bond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC₅₀ values of 0.108, 0.585 and 0.563 μM respectively .

HY-100719

BRD-6929	HDAC HIV	Infection Cardiovascular Disease
BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase *HDAC1* and *HDAC2* inhibitor with IC₅₀ of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with K_i of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research .

HY-126943

SAHA-BPyne	HDAC	Others
SAHA-BPyne is an activity-based protein profiling (ABPP) probe for detecting HDAC activity, which covalently labels the proximal proteins through a photoactivation. SAHA-BPyne inhibits HDAC activity in HeLa nuclear lysate with an IC₅₀ of less than 5 μM .

HY-157490

*PARP/HDAC-IN-1*	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of PARP and *HDAC. PARP/HDAC-IN-1 inhibits PARP1, PARP2* and *HDAC1* with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-145851

*Top/HDAC-IN-1*	HDAC Topoisomerase Apoptosis	Cancer
Top/HDAC-IN-1 (Compound 29b) is a *topoisomerase/HDAC* dual inhibitor with IC₅₀s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC₅₀ of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells .

HY-157215

HDAC-IN-66

HDAC Cancer

HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .

HDAC-IN-66	HDAC	Cancer
HDAC-IN-66 (compound 2F) is a selective *HDAC* inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .

HY-100384

NKL 22 1 Publications Verification	HDAC	Neurological Disease
NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC₅₀ of 199 and 69 nM for *HDAC1* and *HDAC3, respectively. NKL 22 exhibits selectivity over HDAC*2/4/5/7/8 (IC₅₀≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice .

HY-117394

MD 85

HDAC Cancer

MD 85 is a potent histone deacetylase (HDAC) inhibitor with an EC₅₀ of 5 μM. MD 85 can be used for cancer research .

MD 85	HDAC	Cancer
MD 85 is a potent histone deacetylase (HDAC) inhibitor with an EC₅₀ of 5 μM. MD 85 can be used for cancer research .

HY-155840

KH16	HDAC Apoptosis	Cancer
KH16 is a potent and low nanomolar HDAC inhibitor. KH16 is against class I HDACs HDAC1, HDAC2, and HDAC3, with IC₅₀ ?values ranging from 6 to 34 nM. KH16 induces cell apoptosis and is against tumor cells with various gene expression patterns .

HY-142706

*MAO A/HDAC-IN-1*	Monoamine Oxidase HDAC	Cancer
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC*-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149819

*CDK/HDAC-IN-3*	HDAC CDK	Cancer
CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC₅₀ values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .

HY-149208

HDAC-IN-53	HDAC Apoptosis	Cancer
HDAC-IN-53 is an orally active, and selective *HDAC1-3* inhibitor with IC₅₀ values of 47 nM, 125 nM, and 450 nM, respectively. HDAC-IN-53 does not inhibit class II HDACs (HDAC4, 5, 6, 7, 9; IC₅₀>10 μM). HDAC-IN-53 induces caspase-dependent apoptosis. HDAC-IN-53 significantly inhibits the growth of human tumor xenografts in nude mice and murine tumor growth in immune-competent mice bearing MC38 colon cancer .

HY-154855

HDAC-IN-56	HDAC	Cancer
HDAC-IN-56 ((S)-17b) is an orally active class I histone deacetylase (HDAC) inhibitor with IC₅₀ values of 56.0 ± 6.0, 90.0 ± 5.9, 422.2 ± 105.1, >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC4-11, respectively. HDAC-IN-56 has potent inhibitory activity while strongly increasing intracellular levels of acetylhistone H3 and P21 and effectively inducing G1 cell cycle arrest and apoptosis.HDAC-IN-56 has antitumor activity .

HY-155329

GK718	HDAC	Inflammation/Immunology
GK718 is a *HDAC1/3* inhibitor (IC₅₀: 259 and 139 nM respectively). GK718 increased acetylated histone H3 level in cells. GK718 inhibits Bleomycin (HY-108345) induced pulmonary fibrosis in mice .

HY-144893

OKI-006	HDAC	Cancer
OKI-006 is a potent and orally active inhibitor of histone deacetylase (HDAC). OKI-006 is a unique congener of the natural product HDAC inhibitor largazole. Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. OKI-006 has the potential for the research of cancer disease .

HY-161350

*ALK/HDAC-IN-1*	Anaplastic lymphoma kinase (ALK) HDAC	Cancer
ALK/HDAC-IN-1 is a dual inhibitor for ALK and HADC6, with IC₅₀s of 16 nM and 1.03 μM, respectively. ALK/HDAC-IN-1 exhibits antitumor activity .

HY-149285

NT160	HDAC	Neurological Disease
NT160 is a highly potent class-IIa HDAC inhibitor with an IC₅₀ value of 0.046 μM. NT160 can be used for the research of central nervous system diseases .

HY-19350

BML-210 1 Publications Verification	HDAC Apoptosis	Cancer
BML-210 is a potent *HDAC* inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC₅₀ of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice .

HY-152226

MC2590	HDAC Apoptosis	Cancer
MC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC₅₀s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC₅₀s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction .

HY-118421

Nullscript	Parasite HDAC	Infection
Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid . Scriptaid is a representative HDAC inhibitor . Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC₅₀ value of 2.1 μM .

HY-156094

*JMJD3/HDAC-IN-1*	HDAC Histone Demethylase Apoptosis	Cancer
JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC₅₀=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion .

HY-145406

IHCH-3064	Adenosine Receptor HDAC	Inflammation/Immunology Cancer
IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.

HY-152225

MC2625	HDAC Apoptosis	Cancer
MC2625 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2625 show selective HDAC3 and HDAC6 inhibition with IC₅₀s of 80 nM and 11 nM. MC2625 increases acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells (CSCs) growth by apoptosis induction .

HY-161149

CM-1758	HDAC	Cancer
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells .

HY-10226

JNJ-16241199 R306465	Apoptosis HDAC	Cancer
JNJ-16241199 is an orally active, selective *hydroxamate-based histone deacetylase (HDAC)* inhibitor, with the IC₅₀ of 3.3 nM and 23 nM for *HDAC1* and *HDAC8, respectively. JNJ-16241199 induces histone 3 acetylation and strongly increases the expression of p21 ^waf1, ^cip1 in A2780 ovarian carcinoma cells. JNJ-16241199 induces cell apoptosis* and shows anticancer activity in a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .

HY-N8707

Homobutein	Parasite HDAC NF-κB	Infection Inflammation/Immunology Cancer
Homobutein a natural chalcones (can be found in many medicinal plants, fruits, vegetables, spices and nuts), is a potent *HDACs/NF-κB* dual inhibitor with IC₅₀s of 190 and 38 μM, respectively. Homobutein also a chelator of iron (II and III) cations, shows various activities, including anticancer, anti-inflammatory, antiparasite and antioxidation .

HY-118052

BPKDi	PKD	Cardiovascular Disease
BPKDi is a potent bipyridyl PKD inhibitor with IC₅₀s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes .

HY-155248

HL23	HDAC	Cancer
HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .

HY-151896

HDAC6-IN-14

HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15144

Trichostatin A Maximum Cited Publications 108 Publications Verification TSA	Structural Classification Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC .

HY-N11692

9-Hydroxyoctadecanoic acid 9-Hydroxystearic acid; 9-HSA	Apocynaceae Structural Classification Strophanthus sarmentosus DC. Ketones, Aldehydes, Acids Source classification Plants	HDAC
9-Hydroxyoctadecanoic acid (9-HSA) is an *HDAC1* inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM. 9-Hydroxyoctadecanoic acid shows anticancer activity .

HY-N0141

Parthenolide 20+ Cited Publications (-)-Parthenolide	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Euchresta formosana (Hayata) Ohwi Disease Research Fields Cancer	NF-κB Autophagy Mitophagy Apoptosis
Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits *HDAC1* protein without affecting other class I/II HDACs.

HY-N0071

Crotonoside Isoguanosine	Alkaloids Structural Classification Classification of Application Fields Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and *HDAC3/6*, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-N8707

Homobutein	Classification of Application Fields Source classification Plants Compositae Infection Chalcones Flavonoids Millettia pachyloba Drake Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Parasite HDAC NF-κB
Homobutein a natural chalcones (can be found in many medicinal plants, fruits, vegetables, spices and nuts), is a potent *HDACs/NF-κB* dual inhibitor with IC₅₀s of 190 and 38 μM, respectively. Homobutein also a chelator of iron (II and III) cations, shows various activities, including anticancer, anti-inflammatory, antiparasite and antioxidation .

HY-10585A

Valproic acid sodium 30+ Cited Publications Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585

Valproic acid 30+ Cited Publications Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-135476

Depudecin (-)-Depudecin	Structural Classification Natural Products Source classification Plants Brassicaceae Brassica campestris L.	HDAC
Depudecin ((-)-Depudecin) is a histone deacetylase (HDAC) inhibitor. Depudecin can be isolated from the fungus Alternaria brassicicola .

HY-N4315

Pomiferin NSC 5113	Classification of Application Fields Source classification Phenols Polyphenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Cancer	HDAC mTOR
Pomiferin (NSC 5113) acts as an potential inhibitor of *HDAC, with an IC₅₀* of 1.05 μM, and also potently inhibits mTOR (IC₅₀, 6.2 µM).

HY-N6017

Bakkenolide A	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Disease Research Fields Cancer Corethrodendron multijugum (Maximowicz) B. H. Choi & H. Ohashi	HDAC
Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways .

HY-P2698

1-Alaninechlamydocin	Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HDAC Apoptosis
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent *HDAC* inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	Alkaloids Structural Classification Microorganisms other families Classification of Application Fields Other Alkaloids Source classification Plants Disease Research Fields Cancer	HDAC Amyloid-β
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-N2345

Procyanidin B3	Flavonoids other families Classification of Application Fields Functional Molecules Source classification Research of Health Products Phenols Polyphenols Plants Biflavones Disease Research Fields Cancer	Histone Acetyltransferase
Procyanidin B3 is a natural product, acts as a specific HAT inhibitor, binds to the other site of p300 instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase) .

HY-126566

Trichostatin C	Structural Classification Natural Products Microorganisms Source classification	Fungal HDAC Apoptosis
Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer . Trichostatin C induces differentation of Friend leukemic cells . Trichostatin C exhibits antifungal activity .

HY-N2609

7,4'-Dihydroxyflavone 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Leguminosae Source classification Phenols Polyphenols Plants Disease Research Fields Glycyrrhiza uralensis Fisch. Endocrinology	CCR NF-κB
7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC₅₀=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production . 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC₅₀ value of 1.4 µM .

HY-126052

Gnetol	Structural Classification Stilbenes Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Gnetaceae Plants Disease Research Fields Gnetum montanum Markgr.	COX Tyrosinase HDAC
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and *HDAC. Gnetol is a potent tyrosinase* inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-W009732

Sinapinic acid 3 Publications Verification Sinapic acid	Monophenols other families Classification of Application Fields Simple Phenylpropanols Source classification Phenols Metabolic Disease Phenylpropanoids Plants Disease Research Fields	HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species Apoptosis
Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of *HDAC, with an IC₅₀* of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .

HY-N7676

Marein	Cardiovascular Disease Flavonoids Chalcones other families Classification of Application Fields Neurological Disease Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a *HDAC* inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-13755

Sulforaphane 30+ Cited Publications	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of *HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1* expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

HY-B0809

Theophylline 5+ Cited Publications 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Source classification Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Alkaloids Microorganisms Immune System Disorder Disease markers Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809R

Theophylline (Standard) 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Structural Classification Alkaloids Immune System Disorder Classification of Application Fields Source classification Disease markers Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

Cat. No.	Product Name	Chemical Structure

HY-12163S

Entinostat-d4
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-B0809S

Theophylline-d6
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-15654S

Phenylbutyrate-d11 sodium
Phenylbutyrate-d₁₁ (sodium) is deuterium labeled Sodium 4-phenylbutyrate. Sodium 4-phenylbutyrate (4-PBA sodium) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research[1].

HY-A0281S

4-Phenylbutyric acid-d11
4-Phenylbutyric acid-d₁₁ is the deuterium labeled 4-Phenylbutyric acid. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.

HY-A0281S3

4-Phenylbutyric acid-d2
4-Phenylbutyric acid-d₂ is the deuterium labeled 4-Phenylbutyric acid[1]. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.

HY-A0281S2

4-Phenylbutyric acid-d5
4-Phenylbutyric acid-d₅ is the deuterium labeled 4-Phenylbutyric acid[1]. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research[2][3][4].

HY-10528S

Tasquinimod-d3
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of *HDAC4* with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Cat. No.	Product Name		Classification

HY-126943

SAHA-BPyne		Alkynes
SAHA-BPyne is an activity-based protein profiling (ABPP) probe for detecting HDAC activity, which covalently labels the proximal proteins through a photoactivation. SAHA-BPyne inhibits HDAC activity in HeLa nuclear lysate with an IC₅₀ of less than 5 μM .

HY-142706

*MAO A/HDAC-IN-1*		Alkynes
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC*-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163143

HDAC8-IN-6

Alkynes

HDAC8-IN-6 (compound 3) is a potent HDAC8 inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active *HDAC6* inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid		Alkynes
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of *HDAC* inhibition (IC₅₀=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151872

HDAC-IN-48		Alkynes
HDAC-IN-48 is a potent *HDAC* inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI₅₀~20 nM). HDAC-IN-48 consists of harmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits *HDAC* proteins . HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10223

CUDC-101 5+ Cited Publications		Alkynes
CUDC-101 is a potent inhibitor of *HDAC, EGFR, and HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks